Drug Profile
Diazoxide choline controlled release - Soleno Therapeutics
Alternative Names: C601; C602; DCCR; DCCR - Soleno Therapeutics; Diazoxide choline; Diazoxide choline controlled release; Diazoxide-choline-controlled-release-EssentialisLatest Information Update: 10 Oct 2023
Price :
$50
*
At a glance
- Originator Essentialis
- Developer Essentialis; Soleno Therapeutics
- Class Antihyperlipidaemics; Antihypertensives; Antihypoglycaemics; Benzothiadiazines; Obesity therapies; Peripheral vasodilators; Small molecules
- Mechanism of Action Potassium channel agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Prader-Willi syndrome
- Phase II Hypertriglyceridaemia
- Discontinued Hypoglycaemia; Obesity
Most Recent Events
- 04 Oct 2023 Soleno Therapeutics completes an open-label extension phase III trial for Prader-Willi syndrome (In adolescents, In adults, In children) in USA and UK (NCT03714373) (EudraCT2018-004216-22)
- 26 Sep 2023 Soleno Therapeutics announces intention to submit new drug application to US FDA for Prader-Willi syndrome in mid-year 2024
- 26 Sep 2023 Topline efficacy and adverse events data from a phase III trial in Prader-Willi syndrome released by Soleno Therapeutics